Augmenta Bioworks discovers new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity.
Our technology pinpoints the protective immune response of individuals and translates discoveries into therapies.
The cure within.
The immune system relies upon a diverse repertoire of B and T cells to ward off disease. With billions of cells, our adaptive immune system is a formidable opponent to everything from colds, to cancer to cartons of old milk.
Augmenta’s technology finds the needle in the haystack – that one cell, out of billions of cells, out of billions of people, that holds the cure. With the power of modern molecular biology, that winning lottery ticket can be spread and shared by everyone.
We utilize advanced automation, microfluidics, high throughput DNA sequencing, and massively scalable computational analysis to identify immune receptors and their antigen specificity. We provide scientists an unprecedented view of the immune system to guide development of new therapeutics.
We work with leading pharmaceutical companies, biotechnology companies, and research institutions to discover new therapies through our technology platform. Contact us if you would like more information about ways we can work together.
Knowing how vaccines modify the immune system is crucial to improving vaccine efficacy. Our DeepGrid (TM) platform gives an unprecedented view of the changes in the immune repertoire upon antigen exposure.
Our DeepGrid (TM) platform can be used to discover new ways of modulating the immune system to fight disease. DeepGrid (TM) is particularly well suited for the discovery of anti-idiotypic antibodies and characterizing responses to immunotherapeutics.
Therapeutic antibodies are a key class of drugs. Our discovery platform identifies new and better antibodies against targets in cancer and infectious disease, derived from natural human immunity.
New therapeutic modalities, such as CAR-T therapies, rely heavily on the ability to specifically target diseased tissue and differentiate it from normal tissue. Our platform is being used to discover new targets and receptors for CAR-T therapy.
Join us!
Join our team to revolutionize the way we use the immune system to fight disease. If you are a Research Scientist, Molecular Bioengineer, Computational Biologist, Automation Engineer, Research Associate, Maker, Builder, Do-er, Relentless Pursuer of Knowledge, Contact Us!